Previous 10 | Next 10 |
2024-03-26 11:34:10 ET More on cannabis stocks Holders Of Trulieve Should Sell It Trulieve Cannabis: Up Over 122% In 2024, But Where Does It Go Next? Trulieve's Triumph: Navigating Growth And 280E Tax In The Green Rush Americans overwhelmingly support cannabi...
2024-03-25 15:06:06 ET More on marijuana companies Investors Have Another Chance To Sell Curaleaf Curaleaf: New York To The Rescue Curaleaf: Wild Divide Between Wall Street And SA Analysts Sentiments Cannabis stocks spike as VP Kamala Harris urges immediate r...
2024-03-08 11:37:43 ET More on cannabis stocks Verano Holdings: Temporary Setbacks, But Potential For Long-Term Gains Cannabis stocks rebound amid DEA rescheduling review Germany legalizes cannabis with restrictions Verano Holdings reports Q4 results ...
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida. A live...
2024-02-18 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-07 22:18:05 ET Ascendis Pharma A/S (ASND) Q4 2023 Earnings Conference Call February 7, 2024 04:30 PM ET Company Participants Timothy Lee - IR Jan Mikkelsen - President and CEO Scott Smith - EVP and CFO Conference Call Participants Jessica Fye ...
2024-02-07 16:41:12 ET More on Ascendis Pharma Ascendis Pharma's Ambitious Vision 2030 Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For Ascendis Pharma FY 2023 Earnings Preview Ascendis, Frazier launch new ophthalmology company cal...
Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024 TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024 Total Q4 revenue of €138 million including SKYTROFA ® ...
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details: A live webcast of the event will be available via the Inves...
Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...